Selegiline is an irreversible MAO-B inhibitor used orally as adjunctive therapy in Parkinson disease and as a transdermal system for major depressive disorder. At recommended Parkinson doses it is relatively selective for MAO-B, but selectivity can diminish at higher exposures, increasing risks of hypertensive crisis and serotonergic drug interactions. The transdermal antidepressant product carries the antidepressant boxed warning for suicidal thoughts and behaviors in younger patients.
Concomitant meperidine, tramadol, methadone, propoxyphene, cyclobenzaprine, dextromethorphan, St. John's Wort, or another MAOI2
The bottom line
Evidence rating strong. Most-documented uses: adjunctive treatment of parkinson disease in patients receiving levodopa/carbidopa, reduction in parkinson off time, treatment of major depressive disorder with the transdermal system. 3 sources indexed (1989–2025), with 5 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Selegiline irreversibly inhibits monoamine oxidase B, reducing dopamine metabolism in the brain and increasing dopaminergic activity in Parkinson disease. Transdermal dosing produces higher systemic selegiline exposure and antidepressant effects through broader central monoamine modulation while partly bypassing gut first-pass MAO-A inhibition at the lowest patch dose. Loss of MAO selectivity, serotonergic combinations, sympathomimetics, and tyramine-rich foods at higher-risk doses can produce severe toxicity.1,2
Class
Monoamine oxidase B inhibitor
Absorption
Water-soluble; take with food
Dosing
Dosing & protocol.
Common range
Oral Parkinson dosing is commonly 5 mg twice daily with breakfast and lunch, maximum 10 mg/day. Orally disintegrating tablets are typically 1.25-2.5 mg once daily before breakfast. Transdermal antidepressant dosing is 6 mg/24 hours once daily, with possible increases to 9 or 12 mg/24 hours.
Recommended form
Oral capsule or tablet for Parkinson disease; transdermal patch for major depressive disorder
Oral capsules are usually taken with breakfast and lunch to reduce insomnia. Orally disintegrating tablets should be taken before breakfast without liquid. Dietary tyramine restriction is required for higher-dose transdermal patches and if MAO-A inhibition is clinically relevant.3
Safety
Full safety detail.
Side effects
Nausea
Dizziness
Insomnia
Orthostatic hypotension
Dyskinesia or hallucinations when combined with levodopa
Hypertensive reactions with tyramine or sympathomimetics
Children younger than 12 years for the transdermal system due to hypertensive crisis risk3
High-tyramine foods must be avoided with 9 mg/24 hour and 12 mg/24 hour transdermal dosing and for 2 weeks after dose reduction or discontinuation from those doses3
Interactions
Interaction records.
DangerousContraindicated
Tyramine / High-Tyramine Foods
Selegiline can act as a monoamine oxidase inhibitor depending on formulation and dose. Systemic or higher-dose MAOI exposure can reduce tyramine breakdown, so high-tyramine foods may trigger sudden, severe blood-pressure elevation and hypertensive crisis.
Recommendation: Follow the prescriber-specific tyramine restrictions for your selegiline formulation and dose. Avoid high-tyramine foods whenever MAOI dietary restrictions apply.
5-HTP increases serotonin synthesis while Selegiline reduces monoamine breakdown. Combining them can cause dangerous serotonergic excess and serotonin syndrome.
Recommendation: Do NOT combine 5-HTP with Selegiline. Use only if the prescriber managing Selegiline explicitly directs it and provides washout instructions.
Rhodiola is promoted for stimulant and monoaminergic effects. Combining it with MAO-B inhibition may increase agitation, insomnia, blood pressure, or serotonergic symptoms.
Recommendation: Avoid unless the prescriber specifically approves; monitor blood pressure and neuropsychiatric symptoms if exposure has already occurred.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
1
1Effect of deprenyl on the progression of disability in early Parkinson's diseaseNeeds reviewNo linkParkinson Study Group · New England Journal of Medicine · 1989
The DATATOP trial supported clinical benefit of deprenyl in early Parkinson disease, though interpretation included symptomatic effects.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Selegiline in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.